Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002071 · ClinicalTrials.gov registry record · NA

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

A NA study of HIV Infections and Cytopenias, sponsored by Ortho Pharmaceuticals.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002071: Completed NA study of HIV Infections and Cytopenias, sponsored by Ortho Pharmaceuticals.

NCT00002071 is a NA study of HIV Infections and Cytopenias that has completed, run by Ortho Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002071, a NA study of HIV Infections and Cytopenias, has completed, sponsored by Ortho Pharmaceuticals.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To determine the safety and efficacy of erythropoietin administered to AIDS patients with anemia secondary to their disease and/or concomitant zidovudine (AZT) therapy.

Conditions Studied

HIV Infections Cytopenias

Interventions

  • DRUG Epoetin alfa

Study Locations (1)

New Jersey

  • Ortho Pharmaceutical Corp - Raritan

Trial Details

FieldValue
Phase NA
Ortho Pharmaceuticals

6 total trials

What the finished NCT00002071 record still lists

NCT00002071 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Epoetin alfa is the first listed.

NCT00002071 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002071 about?

NCT00002071 is a clinical study titled "A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy". To determine the safety and efficacy of erythropoietin administered to AIDS patients with anemia secondary to their disease and/or concomitant zidovudine (AZT) therapy.

What is the current status of trial NCT00002071?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002071 study?

This clinical trial studies the following conditions: HIV Infections, Cytopenias.

What interventions are being tested in trial NCT00002071?

The interventions under investigation include: Epoetin alfa (DRUG).

Who is sponsoring clinical trial NCT00002071?

This trial is sponsored by Ortho Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002071 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002071, the US trial registry maintained by the National Library of Medicine. NCT00002071 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.